Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 10/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.35 |
| ▸ | CLK3 | P49761 | 8/20 | 0.35 |
| ▸ | WNT1 | P04628 | 2/20 | 0.35 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24202536 | 0.69 | GRM2 (0.42) | GRM2BACE1TLR7 | |
| SCHEMBL3400443 | 0.67 | ALDH1A1 (0.53) | GRM2BACE1TLR7 | |
| SCHEMBL24522243 | 0.67 | SIGMAR1 (0.46) | GRM2TLR7 | |
| SCHEMBL25181316 | 0.67 | PRMT6 (0.45) | GRM2BACE1TLR7 | |
| SCHEMBL12176281 | 0.67 | ALDH1A1 (0.51) | CNR2 | |
| SCHEMBL3992623 | 0.66 | CYP3A4 (0.56) | — | |
| SCHEMBL15274470 | 0.66 | GRM2 (0.40) | GRM2BACE1CLK2DYRK1ACLK3 | |
| Hydrochloric Acid SCHEMBL25412712 | 0.65 | CYP3A4 (0.54) | — | |
| SCHEMBL12074618 | 0.65 | ALDH1A1 (0.48) | GRM2TLR7 | |
| SCHEMBL2558372 | 0.64 | HRH3 (0.40) | GRM2BACE1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | GRM2 3632/4885PRMT5 797/4885WDR77 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.